Tissue inhibitor of metalloproteinases-3 (TIMP-3) is endocytosed, but its regulatory mechanism is not well understood. Result: TIMP-3 endocytosis occurs mainly through low-density lipoprotein receptor-related protein-1 (LRP-1), but shed sLRP-1 binds TIMP-3. Conclusion: TIMP-3-sLRP-1 complexes are retained extracellularly with metalloproteinase inhibitory activity. Significance: LRP-1 is the master regulator of extracellular levels of TIMP-3.
INTRODUCTION
The tissue inhibitors of metalloproteinases (TIMPs) are a family of proteins that regulate the activity of metalloproteinases through formation of tight, non-covalent complexes in a 1:1 stoichiometry (1). Among the four mammalian TIMPs, TIMP-3 is unique in a number of respects. It has a broader inhibitory profile than the other TIMPs, being able to inhibit matrix metalloproteinases (MMPs) and the related metalloproteinases of the ADAM (a disintegrin and metalloproteinase) and the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) families (1) . TIMP-3 is the only member of the family that can bind to the extracellular matrix (ECM) (2, 3) , while the other TIMPs are readily extracted from the tissue. Studies using TIMP-3-null mice have indicated that it is the major regulator of metalloproteinase activities in vivo. Ablation of the Timp3 gene leads to a number of defects in mice, including impaired lung development (4), dilated cardiomyopathy (5) , increased apoptosis during mammary gland involution (6) , and accelerated development of osteoarthritis upon aging (7) . These are due to dysregulation of ECM turnover. In addition, uncontrolled activity of ADAMs, particularly ADAM17, resulted in elevated levels of TNFα and increased inflammation in murine models of liver regeneration (8) , sepsis (9) , and antigen-induced arthritis (7) , and the phenotypes of the Timp3-null mouse are reflected in a number of human pathologies (see ref. (1) for review). Thus, there is considerable interest in understanding factors regulating TIMP-3 levels, and it has been shown that transcription of TIMP-3 can be increased by the histone deacetylase SirT1 (10) and growth factors such as TGFβ (11) and oncostatin M (12) and reduced by promoter methylation (13) . Translation of TIMP-3 can be reduced by miR-21 (14) , miR-221 and miR-222 (15) , miR-181b (16) and miR-206 (17) .
We have recently shown that TIMP-3 levels can be post-translationally regulated by endocytosis and intracellular degradation and suggested that this is an important factor determining extracellular levels of TIMP-3 (18) . In the previous studies we used endocytic blockers to demonstrate the cellular uptake of TIMP-3. For example, HTB94 chondrosarcoma cells transfected with an expression plasmid for TIMP-3 produced high levels of TIMP3 mRNA, but TIMP-3 protein was not detected in the conditioned medium. When heparin, pentosan polysulfate (PPS), or receptor-associated protein (RAP), an antagonist of ligand binding to lowdensity lipoprotein (LDL) receptor and related receptors, was added to the cells, TIMP-3 accumulated in the medium. These studies suggested that the receptor responsible for TIMP-3 endocytosis is a member of the LDL receptor-related protein (LRP) family (18) . There are 13 members in the mammalian LDL receptor family that endocytose a wide variety of ligands and deliver them to endosomes for degradation (19) . Among them, LDL receptorrelated protein 1 (LRP-1) endocytoses more than 30 ligands, including proteinase-inhibitor complexes and ECM proteins, making it an important regulator of ECM composition and turnover (20) . LRP-1 is comprised of 2 chains, a 515 kDa α-chain that interacts with ligands via its 4 clusters of LDL receptor type A repeats, and a non-covalently associated 85 kDa β-chain that tethers the receptor in the membrane and interacts with intracellular adaptors to direct endocytosis via clathrin-coated pits (20) . LRP-1 can be shed from cell membranes, releasing a soluble form of the receptor, sLPR-1, that can act as a competitive inhibitor of ligand endocytosis (21, 22) .
In this report, we used metabolically radiolabelled, isolated recombinant [
35 S]TIMP-3 to investigate the endocytic pathways for TIMP-3 in more detail and analyzed the distribution of radioactivity in different cell fractions over time. Using LRP-1-deficient cells and sulfated proteoglycan mutant cells, we examined the contribution of LRP-1-dependent and LRP-1-independent pathways of TIMP-3 endocytosis. More importantly, our study has revealed that LRP-1 shed from the cell surface (sLRP-1) also binds to extracellular TIMP-3 and sequesters TIMP-3 in the medium and that TIMP-3 bound to sLRP-1 retained metalloproteinase inhibitory activity. This suggests that LRP-1 is a master regulator of extracellular levels of TIMP-3 and regulates ECM catabolism.
EXPERIMENTAL PROCEDURES
Materials -Heparin, de-N-sulfated heparin, chondroitin sulfate, hyaluronan and pronase were from Sigma-Aldrich (Dorset, UK); dermatan sulfate from Calbiochem (Nottingham, UK); PPS from Arthropharm (Sydney, Australia) and GM6001 from Elastin Products Co (Owensville, MOS, USA). Dulbecco's modified Eagle's medium (DMEM), DMEM without L-glutamine or phenol red, L-glutamine, penicillin/streptomycin, fetal calf serum (FCS), hygromycin B, amphotericin B and trypsin-EDTA from PAA Laboratories (Somerset, UK); DMEM without L-glutamine, cysteine, methionine or cystine from MP Biomedicals (Solon, OH, USA). The catalytic domain of human MMP-1 (24); recombinant His-tagged RAP (25) , ADAMTS-4 lacking the C-terminal spacer domain (26) and non-radiolabelled FLAG-tagged TIMP-3 (27) were prepared as previously described.
Cell culture -HTB94 human chondrosarcoma and THP-1 human monocytic acute leukaemia cell lines were from American Culture Type Collection (Manassas, VA, USA). Human uterine cervical fibroblasts were kindly provided by Akira Ito (Tokyo University of Pharmacy and Life Sciences, Japan). CHO-K1 and CHO-745 (28) were generously provided by Jeffrey Esko (Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA). MEF-1 and PEA-13 (homozygous LRP-1-deficient) (29) cells were generated as described previously. Syndecan-4-deficient and wild-type MEF (30) were kindly provided by John R. Couchman (Department of Biomedical Sciences and Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark). All cells were maintained in DMEM with 10 % FCS, 100 U/ml penicillin and 100 U/ml streptomycin at 37 ºC in 5 % CO 2 .
Porcine articular cartilage chondrocytes were isolated from metacarpophalangeal joints within 24 h of slaughter (31) . Cartilage was incubated with 1 mg/ml Clostridium histolyticum collagenase (Sigma-Aldrich, Dorset, UK) in 10 ml DMEM with 10 % FCS for 4 h at 37 ºC. The digested material was passed through a cell strainer, washed and cells cultured in DMEM containing 10 % FCS, 100 U/ml penicillin, 100 U/ml streptomycin, 2 mg/ml amphotericin B and 10 mM HEPES at 37 ºC in 5 % CO 2 .
Expression and purification of [ 35 Confocal microscopy analysis of TIMP-3 endocytosis -HTB94, MEF-1 and PEA-13 cells were cultured on 18 mm glass cover slips coated with gelatin (0.1 % w/v). Nonradiolabelled TIMP-3 (40 nM) was added to cells either alone or in combination with heparin (200 µg/ml) or RAP (500 nM) in phenol-red free DMEM with 0.1% FCS (2 h, 37 ºC). Cells were then fixed with 3% paraformaldehyde in PBS (10 min, RT) and blocked with 5% (v/v) goat serum, 3% (w/v) bovine serum albumin in PBS (1 h, RT). Cells were permeabilized with PBS containing 0.1% (v/v) Triton X-100 (15 min, RT) and incubated with anti-FLAG M2 antibody (Sigma-Aldrich, UK, F1804, 5 µg/ml, 1 h, RT). Alexa Fluor 488-conjugated goat anti-mouse IgG (Molecular Probes, Cambridge, UK) was used to visualize the antigen signal (5 µg/ml, 1 h, RT). Actin was stained with Alexa Fluor 568-conjugated phalloidin (Molecular Probes, Cambridge, UK). The signals were analyzed using a CCD camera-equipped microscope (Nikon TE-2000) with a 60× objective lens.
siRNA targeting of syndecan-1 expression -HTB94 cells (1-1.5x10 5 cells) were transiently transfected with 50 nM of two siRNAs targeting syndecan-1 (AM12432 and AM142557, Ambion) or scrambled (Ambion) using Lipofectamine 2000 for 3 h. After 24 and 48 h, expression of syndecan-1 was reduced by about 90% compared to the housekeeping gene GAPDH.
Isolation of sLRP-1 from plasma -sLRP-1 was isolated from fresh-frozen human plasma by a modification of previously published methods (32) . Plasma was diluted 5-fold with equilibration buffer (50 mM citrate, pH 6.0, 75 mM NaCl, 0.02 % NaN 3 ) supplemented with proteinase inhibitor cocktail (P8340, SigmaAldrich, Dorset, UK) and applied to a MacroPrep S ion exchange resin (Bio-Rad, Hemel Hempstead, UK) equilibrated in the same buffer. The resin was extensively washed in equilibration buffer to remove unbound material and bound proteins then eluted in a gradient of 75 to 500 mM NaCl in equilibration buffer over 10 column volumes. Eluted fractions were analyzed by SDS-PAGE with silver staining and immunoblotting for LRP-1 using the 8G1 antibody (Abcam, Cambridge, UK).
ELISA detection of TIMP-3 binding to sLRP-1 -High-binding microtitre plates (Corning, NY, USA) were coated with 0.4 nmol sLRP-1 in 50 mM citrate, pH 6.0, 75 mM NaCl overnight. Wells were blocked using 3 % BSA-PBS (1 h, 37 ºC) and washed in PBS containing 0.1 % (v/v) Tween 20 (Sigma-Aldrich, Dorset, UK) after this and each subsequent step. Wells were then incubated with recombinant TIMP-3 in blocking solution (0.15 -20 nM, 3 h, 37 ºC). Bound TIMP-3 was detected by incubation of wells with murine M2 anti-FLAG antibody (3 h, 37 ºC) and then with an anti-mouse secondary antibody coupled to horseradish peroxidase (1 h, 37 ºC) (DAKO, Ely, UK). Hydrolysis of tetramethylbenzidine substrate (KPL, Gaithersburg, MA, USA) was measured at 450 nm using a BioTek EL-808 absorbance microplate reader (BioTek, Winooski, VT, USA).
Inhibitory activity of TIMP-3 remnants -HTB94 cells were treated with or without TIMP-3 (1 nM) for 0, 24 or 48 h in serum-free, phenol red-free DMEM. Conditioned media were collected and centrifuged (13000 rpm, 15 min, 4 ºC) to remove cell debris. Recombinant ADAMTS-4 lacking the C-terminal spacer domain (1 nM) was incubated with dilutions of the media or with purified recombinant TIMP-3 in assay buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl 2 , 0.05 % Brij, 0.02 % NaN 3 ) for 1 h at 37 ºC. Residual activity against the fluorescent peptide substrate carboxyfluorescein-Ala-Glu~Leu-Asn-Gly-ArgPro-Ile-Ser-Ile-Ala-Lys-N,N,N',N'-tetramethyl-6-carboxyrhodamine (FAM-AE~LQGRPISIAK-TAMRA, custom synthesized by Bachem, Switzerland) was determined (0.5 µM, excitation wavelength 485 nm, emission wavelength 538 nm with 495 nm cut-off) (27) .
Co-immunoprecipitation of sLRP-1 with TIMP-3 -HTB94 cells were incubated in serum-free DMEM for 24 h, the conditioned media collected and centrifuged (13000 rpm, 15 min, 4 ºC) to remove cell debris. TIMP-3-FLAG (1 nM) was added to the conditioned medium (10 ml) and incubated overnight at RT with mixing. The solution was then applied to an anti-FLAG M2-agarose affinity resin (1 ml) equilibrated in TBS and the resin extensively washed with 10 volumes of TBS. Bound proteins were sequentially eluted with 50 mM Tris-HCl, pH 7.5, 10 mM CaCl 2 , 0.2 % NaN 3 containing 1 M NaCl (2 x 0.5 ml) and then with the same buffer containing 150 mM NaCl and 200 µg/ml FLAG peptide (2 x 0.5 ml). Eluted samples were analysed by SDS-PAGE and immunoblotting using M2 anti-FLAG and 8G1
anti-LRP-1 antibodies. A band corresponding to the LRP-1 immunoreactive band was excised from the silver stained gel, digested with trypsin and analyzed by mass spectrometry. Cellular uptake of exogenously added TIMP-3 was also investigated by confocal microscopy. After incubation of HTB94 cells with recombinant TIMP-3-FLAG for 2 h at 37 ºC, punctate staining for TIMP-3-FLAG was detected inside of the cells (Fig. 1B) . This staining was absent in cells incubated without TIMP-3, indicating the specificity of the staining. The amount of intracellular fluorescent signal was greatly reduced by incubation of cells with RAP (500 nM) and completely abolished by incubation with heparin (200 µg/ml).
RESULTS

TIMP-3 is endocytosed by HTB94 cells
TIMP-3 endocytosis is reduced in LRP-1-deficient cells -Since TIMP-3 endocytosis was inhibited by RAP, we postulated that a member of the LRP family of receptors was involved in TIMP-3 endocytosis. We thus compared [
35 S]TIMP-3 endocytosis by LRP-1-deficient mouse embryonic fibroblasts (PEA-13 cells) and wild-type cells (MEF-1). As shown in Fig. 2A , [ 35 S]TIMP-3 was readily endocytosed by MEF-1 cells with similar kinetics to that observed in HTB94 cells, but [
35 S]TIMP-3 endocytosis was impaired in PEA-13 cells, with the rate of endocytosis approximately half of that observed in HTB94 and MEF-1 cells (Fig.  2B) . This indicates that LRP-1 mediates a major pathway for TIMP-3 endocytosis, but that an LRP-1-independent pathway also operates in these cells. Similar results were obtained using confocal microscopy, with endocytosed TIMP-3-FLAG visible in vesicles within MEF-1 cells, but lower intracellular staining observed in PEA-13 cells (Fig. 2C) . RAP inhibited [
35 S]TIMP-3 endocytosis and degradation by MEF-1 cells to the level observed in PEA-13 cells ( Fig. 2A and  B) . In contrast, RAP had no effect on [
35 S]TIMP-3 endocytosis by PEA-13 cells. Based on these observation we propose that LRP-1 is the only member within the LRP family that mediates [ 35 S]TIMP-3 endocytosis in these cells.
On the other hand, heparin strongly inhibited [
35 S]TIMP-3 endocytosis by both MEF-1 and PEA-13 cells ( Fig. 2A and B) . In this case, only a minimal decrease in TCAinsoluble radioactivity and little increase in TCA-soluble radioactivity in the medium were observed, and [
35 S]TIMP-3 was barely detectable in the cell-associated layer.
We Since heparin inhibits TIMP-3 endocytosis by cells lacking HSPG and CSPG, we tested whether heparin can directly interfere the binding of TIMP-3 to LRP-1. We isolated sLRP-1 from human plasma and measured binding of TIMP-3 and TIMP-3-heparin complexes to immobilized sLRP-1 by ELISA. TIMP-3 bound readily to LRP-1, but upon preincubation with 100 µg/ml heparin, binding of TIMP-3 to LRP-1 was completely abolished Fig.  3C) .
sLRP-1 inhibits TIMP-3 endocytosisDuring the course of this study we noticed that for all the cell lines we tested, TIMP-3 endocytosis was initially fast, but decreased over time and little endocytosis was observed after 10 h. [ 35 S]TIMP-3 remaining in the medium at 24 h ([ 35 S]TIMP-3 remnants) appeared intact by reducing SDS-PAGE and autoradiography, with no fragmentation evident. The ability of TIMP-3 remnants to inhibit metalloproteinase activity was assessed by adding 1 nM TIMP-3 to HTB94 cells for 0, 24 or 48 h, after which time TIMP-3 remnants in the media were harvested and titrated against 1 nM ADAMTS-4 in vitro. TIMP-3 collected after 0 h incubation on HTB94 cells completely inhibited 1 nM ADAMTS-4 (Fig. 4A) . TIMP-3 harvested after 24 and 48 h incubation on HTB94 cells inhibited ADAMTS-4 activity by 60%, indicating that while the concentration of TIMP-3 in the medium had been reduced by endocytosis, the TIMP-3 remnants remaining in the medium retained their full inhibitory activity against metalloproteinases. These data indicate that TIMP-3 remnants had not undergone any substantial structural modification or inactivation.
We therefore considered whether the reduced rate of [
35 S]TIMP-3 endocytosis was due to a change in the endocytic capacity of the cells. Although TIMP-3 has been shown to induce apoptosis in a variety of cell types (34), we found that incubation of HTB94 cells with 1 nM [
35 S]TIMP-3 for 24 h had no effect on cell viability as measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Furthermore, pretreatment of HTB94 cells with non-radiolabelled TIMP-3 for 24 h did not alter the rate of endocytosis of subsequently added [ 35 (Fig. 4D ). Based on these results, we postulated that TIMP-3 became resistant to endocytosis as a result of association with sLRP-1 shed from cells into the conditioned medium during the culturing period. sLRP-1 accumulated over time in the conditioned medium harvested from HTB94 cells grown in serum-free medium in the absence of TIMP-3 (Fig. 4E) . Binding of TIMP-3 to sLRP-1 was investigated first by incubating TIMP-3-FLAG (1 nM) in vitro with the conditioned medium from HTB94 cells. After overnight incubation at ambient temperature, the mixture was applied to an M2 anti-FLAG resin, and bound proteins were eluted with FLAG peptide. Analysis of the eluted samples with the 8G1 anti-LRP-1 antibody indicated that LRP-1 was co-eluted with TIMP-3-FLAG by FLAGpeptide (Fig. 4F) . The identity of the eluted LRP-1 band was further confirmed by mass spectrometry, confirming that TIMP-3 can interact with sLRP-1 shed into the conditioned medium of cells.
We also found that addition of TIMP-3 to HTB94 cells increases the release of sLRP-1 fragments of 500, 215, 160 and 110 kDa into the conditioned medium in a concentrationdependent manner, suggesting that the inhibitor can induce shedding and fragmentation of LRP-1 (Fig. 4G) . When TIMP-3-FLAG (1 nM) was incubated with HTB94 cells for 24 h and conditioned medium was applied to an M2 anti-FLAG resin column, bound TIMP-3-FLAG coeluted with the 500 kDa sLRP-1 and with LRP-1 fragments of 215, 160 and 110 kDa (Fig. 4H) . This indicates that these fragments generated upon addition of TIMP-3 to the cells are capable of binding to the inhibitor.
DISCUSSION
Our study has revealed a new mechanism for regulating levels of TIMP-3 in the extracellular space. We previously reported that levels of this physiologically and pathologically important inhibitor can be post-translationally regulated by endocytosis (18) . TIMP-3 accumulates in the medium of HTB94 chondrosarcoma cells and porcine articular chondrocytes treated with receptor-associated protein (RAP), an antagonist of ligand binding to the LRP family of endocytic receptors (18) . Using radiolabelled TIMP-3 we investigated the kinetics of TIMP-3 endocytosis and degradation by LRP-1-deficient PEA-13 mouse embryonic fibroblasts and their wild-type counterpart. TIMP-3 endocytosis was substantially reduced in LRP-1-deficient PEA-13 cells compared to wild-type cells, indicating that LRP-1 is an important component of the TIMP-3 endocytic machinery. RAP, which inhibits ligand binding to all LRPs, had no effect on the residual endocytosis of TIMP-3 by PEA-13 cells, indicating that LRP-1 is the only member of the LRP family that mediates TIMP-3 endocytosis in mouse embryonic fibroblasts.
We compared the endocytosis of TIMP-3 by several cell types, including chondrosarcoma cells, porcine articular chondrocytes, fibroblasts and monocyte-like THP-1 cells. All cell types showed similar kinetics for TIMP-3 endocytosis. The rate of TIMP-3 endocytosis was not constant over 24 h. After addition of [
35 S]TIMP-3 to cells, endocytosis was initially rapid, but then slowed, so that only minimal endocytosis was observed after 10 h. We demonstrated that this reduction in endocytosis is due to interaction of TIMP-3 with a soluble form of LRP-1 shed from the cell surface into the medium. Different LRP-1 'sheddases' have been described, including ADAM10, ADAM12, ADAM17, MT1-MMP and β-secretase (23, (35) (36) (37) (38) . Although the specific site(s) at which these enzymes cleave LRP-1 have not been characterized, shedding is known to involve cleavage of the β-chain of LRP-1, releasing a fragment of the β-chain in complex with the entire ligand-binding α-chain from the cell membrane (39) . Inflammation is a key stimulus for LRP-1 shedding. For example, interferon γ and LPS stimulate LRP-1 shedding by ADAM17 (35) . Increased levels of sLRP-1 are detectable in the plasma of patients with rheumatoid arthritis, systemic lupus erythematous (35) and liver disease (32) . sLRP-1 and lower molecular weight fragments of LRP-1 are found in brain and in cerebral spinal fluids, and are increased in older people (23) . Cholesterol depletion has also been found to stimulate LRP-1 shedding by MT1-MMP and ADAM12 (36) . We observed LRP-1 shedding in the absence of any proinflammatory stimuli, and addition of IL-1 had no effect on the rate of TIMP-3 endocytosis by primary chondrocytes (S. Scilabra and H. Nagase, unpublished observations). Since a number of the proposed LRP-1 'sheddases' are metalloproteinases, production of sLRP-1 should be inhibited by metalloproteinase inhibitors such as TIMP-3 and GM6001. However, we found that TIMP-3 could induce shedding of LRP-1 and generation of LRP-1 fragments. A previous report showed that N-TIMP-3 inhibited MT1-MMP-and ADAM12-mediated shedding of LRP-1 (36) . We found that, unlike TIMP-3, N-TIMP-3 did not induce shedding and fragmentation of LRP-1 (S. Scilabra and H. Nagase, unpublished observations), therefore we hypothesize that the C-terminal domain of TIMP-3 can play a crucial role in this process. GM6001 has also been shown to inhibit LRP-1 shedding from macrophages and lung fibroblasts (21, 35 ), but we found that GM6001 had no effect on the rate of [
35 S]TIMP-3 endocytosis by HTB94 cells. This suggests that a GM6001-insensitive sheddase may mediate LRP-1 shedding in HTB94 cells. The stimulus and sheddases responsible for LRP-1 constitutive shedding and TIMP-3 induced shedding in HTB94 cells and chondrocytes are currently under investigation in our laboratory.
Shedding of LRP-1 has numerous consequences. Firstly, it can reduce endocytosis of LRP-1 ligands in a loss-of-function manner by reducing the number of endocytic receptors on the cell surface (21, 36, 38) . Secondly, sLRP-1 can bind to and inhibit endocytosis of its ligands, as we found for TIMP-3, and as has been reported for tPA (32) . By antagonizing LRP-1-mediate endocytosis, sLRP-1 can increase the half-life of TIMP-3 in the extracellular space. More importantly, we found that the TIMP-3-sLRP-1 complex is still able to inhibit metalloproteinases. We found that the ratio between cell surface LRP-1 and sLRP-1 is an important factor that regulates the bioavailability of TIMP-3 in the extracellular space, and hence controls ECM proteolysis and proteolysis of cell surface molecules.
In addition to the LRP-1-mediated pathway, we observed LRP-1-independent endocytosis of TIMP-3 in PEA-13 cells and RAP-treated HTB94, MEFs and CHO cells. Although this is a slower process compared with the LRP-1-mediated endocytosis, it is likely to be receptormediated.
Members belonging to the macrophage mannose receptor protein family may be possible candidates as they have been shown to internalize some LRP-1 ligands and play a crucial role in ECM turnover. For instance, urokinase plasminogen activator receptor-associated protein/endocytic recycling protein Endo180 is expressed in chondrocytes and fibroblasts and is involved in collagen internalization (40, 41) . TIMP-1 and TIMP-2 are also endocytosed by LRP-1 (42, 43) . While TIMP-1 is internalized only in complex with MMP-9, with the binding determinants thought to reside on the MMP-9 (42). TIMP-2 can be endocytosed by LRP-1 both as a free inhibitor and in complex with MMP-2 or proMMP-2 (43). Interestingly, binding of TIMP-2 to HT1080 cells was insensitive to RAP, suggesting that TIMP-2 initially binds to a cell surface receptor other than LRP-1 prior to endocytosis (43) . Furthermore, endocytosis and degradation of TIMP-2 was only partially inhibited by RAP, indicating that an LRP-1-independent endocytic pathway also occurs (43) . These studies thus suggest that both TIMP-2 and TIMP-3 can be endocytosed by LRP-1-dependent and LRP-1-independent pathways. It would be interesting to determine whether TIMP-2 and TIMP-3 share the same the mechanism of LRP-1-independent endocytosis.
Endocytosis of TIMP-3 in all tested cell types was almost completely inhibited by heparin. This suggested that an HSPG or CSPG might participate in TIMP-3 endocytosis, either as a direct endocytic receptor or as a co-receptor of LRP-1. HSPG have been demonstrated to mediate endocytosis of ligands including lipoproteins (44) . Alternatively, HSPG might act as co-receptors of LRP-1-mediated endocytosis as proposed for thrombospondin 1 (45), tissue factor pathway inhibitor (46) , amyloid-β (47) and factor VIII (48) . However, we found that TIMP-3 endocytosis was not affected in xylosyltransferase-deficient CHO-745 cells, indicating that sulfated cell surface proteoglycans are not required for TIMP-3 endocytosis. In line with this finding, TIMP-3 endocytosis was also unimpaired in syndecan-4-null and syndecan-1-silenced cells. We therefore conclude that cell surface HSPG or CSPG do not mediate the LRP-1-independent pathway of TIMP-3 endocytosis.
The unimpaired endocytosis of TIMP-3 in CHO-745 cells nullified our hypothesis that heparin inhibits TIMP-3 endocytosis by blocking interaction with a sulfated cell surface proteoglycan component of the endocytic pathway. Interestingly, heparin has been shown to directly inhibit interaction of other ligands, including factor IXa (49), apolipoprotein A-V (50), C4b-binding protein (51) and PAI-1 (52), to LRP-1. In the case of PAI-1, the heparinbinding and LRP-1-binding regions have been found to overlap (53, 54) . Binding of proteins to heparin is commonly mediated by clusters of positively charged residues (55) . Similarly, binding of protein ligands to LRP-1 and related LDL receptors is often mediated by positive residues, as has been demonstrated for RAP (56, 57) and α 2 M (58). In the case of RAP, crystallography and mutagenesis studies have confirmed that K256 and K270 mediate binding to acidic pockets in the ligand binding motifs of the receptor (56, 57) . Inhibition of TIMP-3 binding to sLRP-1 by heparin suggests that the heparin-binding and LRP-1-binding sites of TIMP-3 may also overlap. The threedimensional structure of full-length TIMP-3 is currently unavailable, but the protein is predicted to contain an extended patch of basic residues, located on the opposite face of the protein to the inhibitory ridge that interacts with metalloproteinase. This may explain why TIMP-3-sLRP-1 complexes retain metalloproteinases inhibition activity.
The phenotypes of the Timp3 -/-mouse reveal the central role of TIMP-3 in regulating activity of MMPs, ADAMs and ADAMTSs. Our study has shown that LRP-1 plays an important role in controlling the extracellular levels of TIMP-3. It is well established that TIMP-3 binds to ECM (2,3), but we have shown here that secreted TIMP-3 can be readily internalized via LRP-1, and this process competes with TIMP-3 binding to the ECM. On the other hand, shed sLRP-1 sequesters TIMP-3 from the above two reactions and increases its availability to extracellular MMPs, ADAMs and ADAMTs. It is notable that shedding of LRP-1 is increased under inflammatory conditions. We therefore propose that LPR-1 is a master regulator of extracellular trafficking of TIMP-3 and the ratio of cell surface LPR-1 and sLRP-1 dictates TIMP-3 availability.
Abbreviations used are: ADAM, a disintegrin and metalloproteinase; ADAMTS, adamalysin with thrombospondin motifs; CSPG, chondroitin sulfate proteoglycan; ECM, extracellular matrix; GAG, glycosaminoglycan; HSPG, heparan sulfate proteoglycan; LDL, low-density lipoprotein; LRP-1, lowdensity lipoprotein receptor-related protein-1; MMP, matrix metalloproteinase; N-TIMP, N-terminal domain of TIMP; PPS, pentosan polysulfate; RAP, receptor associated protein; sLRP-1, soluble LRP-1; TCA, trichloroacetic acid; TIMP, tissue inhibitor of metalloproteinase. Figure 1: TIMP-3 is endocytosed by HTB94 chondrosarcoma cells. A, [ 35 S]TIMP-3 (1 nM) was added to HTB94 chondrosarcoma cells in the absence or presence of RAP (500 nM) or heparin (200 µg/ml), and radioactivity in different cell fractions monitored over time (n=3). TIMP-3, black symbols; TIMP-3 plus 500 nM RAP, open symbols; TIMP-3 plus heparin, grey symbols. B, Confocal microscopy analysis of TIMP-3 endocytosis by HTB94 cells. Cells were incubated for 2 h at 37 °C with TIMP-3-FLAG (40 nM), either alone or with heparin (200 µg/ml) or RAP (500 nM). Control cells were incubated without TIMP-3-FLAG. Cells were washed and permeabilized, and endocytosed TIMP-3-FLAG vizualised using an M2 anti-FLAG antibody and an Alexa 488-labelled secondary antibody (green channel). The cytoskeleton was visualized using Alexa 568-labelled phalloidin (red channel). Images were gathered using a 60× objective lens. Scale bar: 41 µm 
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